Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo meets demand

This article was originally published in The Tan Sheet

Executive Summary

The private labeler increases its manufacturing capacity by 10 percent and its production of OTC tablets by 3 billion a year with the addition of a $25 million, 62,000-square foot facility in Allegan, Mich. The company announces the 18-month construction project Oct. 15, a month after adding a 160,000 square-foot manufacturing facility in its $44 million acquisition of JB Laboratories in nearby Holland, Mich., and a week after acquiring Mexican store-brand manufacturer Laboratorios Diba for $25 million (1"The Tan Sheet" Oct. 13, 2008, p. 3). Spokesman Art Shannon says Perrigo planned the expansion before buying JB and Diba, and it may need more manufacturing capacity. Demand for Perrigo's products "is increasing across the board," he says. "We make 30 billion tablets [annually] and it keeps growing with all the new products that we have. We just need additional manufacturing capacity.

Related Content

Topics

UsernamePublicRestriction

Register

PS102222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel